echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's first!

    The world's first!

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: info

    On March 28, the CDE official website showed that the domestic clinical application of Hebo Medicine’s B7H4x4-1BB double antibody was accepted for the treatment of solid tumors


    HBM7008 was developed by Harbin Pharmaceutical's unique and innovative HBICE platform.


    HBM7008 specifically activates T cells and produces antitumor activity only when it binds to B7H4


    The unique tumor expression specificity and immunomodulatory activity of HBM7008 is expected to produce better efficacy in PD-L1-negative patients or patients who are resistant to PD-1/PD-L1 immunotherapy drugs


    On February 28 this year, HBM7008 was approved for clinical use in Australia


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.